# No alternative to equities 

# While political risk, a second Covid-19 wave, lower economic activity and suppressed inflation might trigger a short-term sell-off, in the medium term a high equity risk premium and low rates will support equities 

Paul Doyle, Head of Europe ex-UK Equities



After a very strong bounce off their March low points, equity markets are now looking stretched. As we experience a second Covid-19 wave the uncertainty is beginning to have an impact on the earnings recovery, and although the US presidential election is now behind us - albeit with the potential for a difficult transition - the newly elected president is likely to continue to put pressure on China.

Corporate earnings revisions have been rising in the US but may now be peaking. In Europe they are flat. ${ }^{1}$ At Columbia Threadneedle Investments we expect a more modest bounce back in earnings next year than many other commentators. Consensus numbers look too high.

What is indisputably positive is the US Federal Reserve's new policy framework, with an explicit plan to let inflation overshoot. Even if inflation rises the Fed will look through it. Eventually that will steepen the interest rate yield curve. Yet the biggest determinant of long-term interest rates is the direction of short rates. If short rates are going to be stuck at low levels for the next four to five years, how can long yields go up?

New Covid-19 lifestyle restrictions, together with less fiscal support, will weigh on economies towards the end of the year.


At the time of writing the emergency US federal unemployment package has lapsed and a new fiscal package has not been agreed. Taken together, delays in the enactment of such a stimulus and a sell-off in US technology stocks have all heightened the short-term risk in markets, although the vaccine news is hugely welcome.

Short-term monetary stimulus, as measured by six-month credit flows, reached an all-time high over the summer, but this is fading. In the US and China such flows peaked at $\$ 700$ billion and $\$ 800$ billion respectively in May. In the eurozone the peak was more than \$1 trillion in July. Together, these flows were even bigger than during in the global financial crisis (GFC). Six-month credit flows have recently fallen to about $\$ 200$ billion each in the US and China. ${ }^{2}$

While we have yet to see the latest numbers for Europe, the picture must be similar. With this happening, fiscal stimulus will take on a more important role.

Watch the equity risk premium Apart from in the very short term there is no alternative to equities, since the global equity risk premium - the difference between the equity earnings yield and real government bond yields - remains so large. The dividend yield for the S\&P 500 Index is currently $1.6 \%$, below its long-term average of $4.3 \%$ but way above the $0.7 \%$ yield on the 10-year US Treasury bond. If dividends paid were to remain at current levels for the next 10 years, the S\&P 500 would need to fall $9 \%$ just to equal the return from the 10-year Treasury. If inflation were to average $2 \%$ over the same 10-year period the S\&P 500 would need to fall $25 \%$ to match the 10-year Treasury. ${ }^{3}$

- The scenario is even more dramatic outside the US: eurozone equities would need to fall 30\% in real terms, and UK equities would need to fall $50 \%$, to match the return from bonds. ${ }^{4}$ None of these scenarios is likely. While the US earnings yield is well below average, the equity risk premium is still high because real bond yields are well into negative territory.

Indeed, the equity risk premium remains around its March level when equity prices hit their lows. Although equity prices have rebounded and dividend yields fallen, the fall in real bond yields has been similar. While the market priced in the temporary Covid-19-linked fall in corporate earnings, which will eventually rebound, it has also priced in the 94bp drop in the risk-free 30-year bond yield since the start of the year. ${ }^{5}$ While the earnings effect is temporary, the discount rate effect is permanent. So in spite of short-term worries, equity prices actually should be higher.

Meanwhile, monetary policy is exceptionally loose. The Fed has promised to keep rates on hold until the economy has reached "maximum employment" and inflation is "on track moderately to exceed $2 \%$ for some time". A majority of the Federal Open Market Committee does not expect to move rates before at least the end of 2023. While bond yields are unlikely to rise in the next few years in the absence of inflation, they are unlikely to fall further given how low they are already. The equity risk premium is high enough that equities can still go higher - even if bond yields rise a little.

## Growth versus value

This prolonged period of low interest rates suggests parallels with the "nifty 50" era of the 1960s and 1970s when 50 quality growth stocks dominated US equity market performance.

Even so, if bond yields only stabilise rather than go up, this could remove a major headwind for banks. Value stocks are now cheaper versus growth stocks than at any point in history - even cheaper than at the height of the dotcom bubble in 2000 (Figure 1). ${ }^{6}$ But they need a catalyst to prompt a rebound. A new fiscal deal and a successful, fully approved and rapidly distributed vaccine might provide that, but we are not there with either quite yet. There are a number of vaccine candidates in phase three trials, and three which so far look to be successful - but we still need some time for final approval, manufacturing and global distribution.


Figure 1: Value stocks are extremely cheap relative to growth stocks


Source: BCA Research Inc, September 2020. Based on relative price/book, price/earnings and dividend yields/IBES/Thomson Reuters and MSCI Inc.

Value tends to outperform growth when the US dollar is weakening and global growth accelerating. Growth stocks did well in the late 1990s when the dollar was strong, while value performed better from 2001-07 when the dollar was weak. If the dollar weakens in the coming months, it could help lift all those value names currently in the doldrums.

## Support for risk assets

With the US election behind us, vaccines should accelerate recovery. It is unlikely that current policy support will change as authorities want to run economies hot to sustain the recovery. That will push equities higher.

Until now, there has been a lot of uncertainty over long-term growth, which has counterbalanced the positive effects of lower rates. It has also reflected deflationary tail risks and fears about the

41 Value stocks are now cheaper versus growth stocks than at any point in history - even cheaper than at the height of the dotcom bubble in 2000
future of the EU and the euro. Now that we are at the beginning of a new cycle, with moderate growth but low inflation and interest rates, policy support should help to reduce the risk of another recession.

The resumption of a zero-interest rate policy will support risk assets for the foreseeable future. In the near term though, the current rise in Covid-19 infections, continued lockdowns, lower economic activity and suppressed inflation expectations (ie, higher real rates) may cause equities to sell off again.

[^0]
## To find out more visit <br> COLUMBIATHREADNEEDLE．COM

Important Information：For use by Professional and／or Qualified Investors only（not to be used with or passed on to retail clients）．This document is intended for informational purposes only and should not be considered representative of any particular investment．This should not be considered an offer or solicitation to buy or sell any securities or other financial instruments，or to provide investment advice or services．Investing involves risk including the risk of loss of principal．Your capital is at risk．Market risk may affect a single issuer，sector of the economy，industry or the market as a whole．The value of investments is not guaranteed，and therefore an investor may not get back the amount invested．International investing involves certain risks and volatility due to potential political，economic or currency fluctuations and different financial and accounting standards．The securities included herein are for illustrative purposes only，subject to change and should not be construed as a recommendation to buy or sell．Securities discussed may or may not prove profitable．The views expressed are as of the date given，may change as market or other conditions change and may differ from views expressed by other Columbia Threadneedle Investments（Columbia Threadneedle）associates or affiliates．

Actual investments or investment decisions made by Columbia Threadneedle and its affiliates，whether for its own account or on behalf of clients，may not necessarily reflect the views expressed．This information is not intended to provide investment advice and does not take into consideration individual investor circumstances．

Investment decisions should always be made based on an investor＇s specific financial needs，objectives，goals，time horizon and risk tolerance．Asset classes described may not be suitable for all investors．Past performance does not guarantee future results，and no forecast should be considered a guarantee either．Information and opinions provided by third parties have been obtained from sources believed to be reliable，but accuracy and completeness cannot be guaranteed．This document and its contents have not been reviewed by any regulatory authority．

In Australia：Issued by Threadneedle Investments Singapore（Pte．）Limited［＂TIS＂］，ARBN 600027 414．TIS is exempt from the requirement to hold an Australian financial services licence under the Corporations Act and relies on Class Order 03／1102 in marketing and providing financial services to Australian wholesale clients as defined in Section 761G of the Corporations Act 2001．TIS is regulated in Singapore（Registration number：201101559W）by the Monetary Authority of Singapore under the Securities and Futures Act（Chapter 289），which differ from Australian laws．

In Singapore：Issued by Threadneedle Investments Singapore（Pte．）Limited， 3 Killiney Road，\＃07－07，Winsland House 1，Singapore 239519，which is regulated in Singapore by the Monetary Authority of Singapore under the Securities and Futures Act（Chapter 289）．Registration number：201101559W．This document has not been reviewed by the Monetary Authority of Singapore．

In Hong Kong：Issued by Threadneedle Portfolio Services Hong Kong Limited 天利投資管理香港有限公司．Unit 3004，Two Exchange Square， 8 Connaught Place，Hong Kong，which is licensed by the Securities and Futures Commission（＂SFC＂）to conduct Type 1 regulated activities（CE：AQA779）．Registered in Hong Kong under the ce（Chapter 622），No． 1173058.

In EMEA：Issued by Threadneedle Asset Management Limited．Registered in England and Wales，Registered No．573204，Cannon Place， 78 Cannon Street，London EC4N 6AG， United Kingdom．Authorised and regulated in the UK by the Financial Conduct Authority．This document is distributed by Columbia Threadneedle Investments（ME） Limited，which is regulated by the Dubai Financial Services Authority（DFSA）．For Distributors：This document is intended to provide distributors＇with information about Group products and services and is not for further distribution．For Institutional Clients：The information in this document is not intended as financial advice and is only intended for persons with appropriate investment knowledge and who meet the regulatory criteria to be classified as a Professional Client or Market Counterparties and no other Person should act upon it．Columbia Threadneedle Investments is the global brand name of the Columbia and Threadneedle group of companies． columbiathreadneedle．com

Issued 11.20 ｜Valid to 06.21 ｜J31073｜ 3333854


[^0]:    ${ }^{1}$ Columbia Threadneedle analysis, September 2020.
    ${ }^{2}$ BCA Research Inc, September 2020.
    ${ }^{3}$ Bloomberg/Columbia Threadneedle analysis, September 2020.
    ${ }^{4}$ Bloomberg/Columbia Threadneedle analysis, September 2020.
    ${ }^{5}$ BCA Research Inc, September 2020.
    ${ }^{6}$ BCA Research Inc, September 2020.

